Linagliptin
8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
Drag to rotate. Structure from PubChem CID 10096344.
Background
Listing
- Schedules
- Schedule 3 to 4
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
1 registered product listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Linagliptin Cancelled | Trajenta | Not stated | Ingelheim Pharmaceuticals (Pty) Ltd û Ferndale | 450557 | S3 to S4 |
Regulatory status
Where S3 to S4 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 3: needs a doctor's prescription, dispensed by a pharmacist. At the most restrictive, Schedule 4: prescription-only medicine. The listings below say which applies to which form, strength or pack size.
Schedule S3 to S4, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Linagliptin
S4: Linagliptin
Consolidated Schedules 06 July 2026, line 6939
S3: Linagliptin
Consolidated Schedules 06 July 2026, line 3898
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.